Otros idiomas CStone Pharmaceuticals

Acciones

2616

KYG2588M1006

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:20 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
0,9 ^HKD	0,00 %		+5,88 %	-60,35 %

24/04	Cstone Pharmaceuticals registra menores pérdidas para 2023 y sus acciones suben casi un 5	MT
23/04	CStone Pharmaceuticals informa de los resultados de ganancias para el año completo finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%	24/04
CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	23/04
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor	09/04
CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA	09/04
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved	15/03
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer	15/03
CStone Pharmaceuticals Booted From Hong Kong Stock Connect; Shares Plunge 25%	04/03
CStone sells to Servier its exclusive rights to TIBSOVO in Greater China and Singapore	22/12
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million	21/12
The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals for $44 million.	21/12
China Includes CStone's Gastrointestinal Stromal Tumor Treatment in National Reimbursement List; Shares Jump 6%	13/12
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma	11/12
China Approves CStone Pharma's Treatment for Esophageal Squamous Cell Carcinoma; Shares Soar 21%	08/12
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma	08/12
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China	02/11
CStone Pharmaceuticals Announces Strategic Partnership and Exclusive Licensing Agreement with Shenyang Sunshine Pharmaceuticals Co., Ltd for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China	01/11
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3Sbio for Nofazinlimab (ANTI-PD-1 Antibody) in Mainland China	01/11
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma	31/10/23
China Approves CStone's Lymphoma Medication	31/10/23
CStone Pharmaceutical Awaits Chinese Approval for Anti-Cancer Drug	24/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas CStone Pharmaceuticals

Acciones

2616

KYG2588M1006

Otros idiomas

Filtros